These cardioprotective effects of Dkk3 are exerted via the inhibition of the Wnt non-canonical ASK1/JNK/p38 signaling pathways [143,145] and has led to the proposal of Dkk3 as a therapeutic target for the treatment of heart failure [146]. The gene discussed is MAPK14; the disease is heart failure.